Objective: Leptin is a key hormone in the control of appetite and body weight. Predominantly produced by white adipose tissue, it acts on the brain to inhibit homeostatic feeding and food reward. Leptin has free access to circumventricular organs, such as the median eminence, but entry into other brain centers is restricted by the bloodebrain and bloodeCSF barriers. So far, it is unknown for which of its central effects leptin has to penetrate brain barriers. In addition, the mechanisms mediating the transport across barriers are unclear although high expression in brain barriers suggests an important role of the leptin receptor (LepR). Methods: We selectively deleted LepR in brain endothelial and epithelial cells of mice (LepR beKO ). The expression of LepR in fenestrated vessels of the periphery and the median eminence as well as in tanycytes was not affected. Results: Perfusion studies showed that leptin uptake by the brain depended on LepR in brain barriers. When being fed with a rewarding high-fat diet LepR beKO mice gained more body weight than controls. The aggravated obesity of LepR beKO mice was due to hyperphagia and a higher sensitivity to food reward. Conclusions: The LepR-mediated transport of leptin across brain barriers in endothelial cells lining microvessels and in epithelial cells of the choroid plexus controls food reward but is apparently not involved in homeostatic control of feeding.
INTRODUCTION
Leptin is a key hormone controlling body weight [1] . With repleted and filled fat depots, adipocytes release leptin into the blood stream. Subsequently, leptin inhibits food intake and stimulates energy expenditure. The important functions of leptin and the leptin receptor (LepR) in body weight regulation are illustrated by the excessive obesity that occurs in mice and humans with inactivating pathogenic variants in the respective genes. For the main metabolic effects of leptin, LepR in neurons is both required and sufficient [2, 3] . LepR in the arcuate nucleus (ARC) and in other nuclei of the mediobasal hypothalamus strongly modulates the homeostatic control of food intake and energy expenditure [4, 5] . In addition, LepR regulates food reward in other brain areas, such as the lateral hypothalamus and the ventral tegmental area (VTA) [6, 7] . Overall, brain access is essential for leptin to exert its physiological actions. This is supported by data showing that brain permeability of leptin is impaired in obesity. Although leptin levels are elevated in plasma of obese subjects, the ratio of CSF to plasma concentrations is decreased in obesity [8, 9] . In preclinical obesity models, leptin only reduces food intake when administered intrathecally but not peripherally [10e12] . These data suggest that reduced brain permeability may contribute to leptin resistance in obesity and may further elevate body weight. Due to its size (16-kDa), leptin is not expected to passively diffuse through tight brain barriers. However, it has direct access to circumventricular organs including LepR-expressing neurons in the mediobasal hypothalamus that are not shielded by the bloodebrain barrier (BBB) [13] . In addition, there is uptake into the choroid plexus and brain parenchyma [14, 15] . Influx of leptin into the brain is partially saturable, indicating that membrane proteins facilitate the uptake of leptin [14] . The example of other peptides similar to leptin in structure and size that cross the BBB via receptor-mediated transcytosis [16] points to a role of LepR in leptin uptake by the brain. Indeed, LepR is required for 1 the transport of leptin by tanycytes in the mediobasal hypothalamus [17] . Moreover, short isoforms of LepR that lack intracellular signaling domains, mainly LepRa and LepRc, are highly expressed in brain barriers, such as the choroid plexus and brain endothelial cells [18e 22] . In mice lacking all LepR isoforms, leptin uptake by the brain has been reported to be diminished supporting a role of LepR in leptin transport across the BBB [22] , although another study using a rat strain deficient of all LepR isoforms found no significant effect of LepR loss on leptin uptake by the brain [23] . Until now, it is unclear whether leptin has to penetrate brain barriers to exert its central effects. Furthermore, current understanding of leptin access to the brain and its role in physiology is potentially confounded by leptin effects on other functional systems. Leptin modulates immunity, the autonomic nervous system, metabolism, and several endocrine axes [24, 25] , all of which have major impact on BBB function. To directly assess the role of LepR in leptin uptake by the brain and to elucidate LepR function in CNS barriers for body weight regulation without interfering factors from the periphery, we aimed to delete all LepR isoforms selectively in brain endothelial cells and the choroid plexus. This goal could be achieved with a mouse line, in which exon 1 of LepR is flanked by loxP sites affecting all isoforms [3] and an inducible Cre driver line that mediates recombination in brain endothelial cells and epithelial cells of the plexus [26, 27] . When deleting LepR in brain endothelial and epithelial cells, the uptake of leptin by the brain was reduced and body weight was increased on a high-fat diet (HFD) but not on normal chow (NCD). Further experiments revealed that LepR in brain barriers inhibits food reward but seems to be dispensable for the homeostatic function of leptin mediated by the mediobasal hypothalamus.
MATERIAL AND METHODS

Mice
All mice were housed in individually ventilated cages under a 12-h light/12-h dark cycle at 23 C, with free access to water and food. Mice with an inducible deletion of LepR in brain endothelial and epithelial cells (LepR beKO ) were generated by crossing LepR Fl (JAX stock #008327) [3] and Slco1c1-CreER T2 [26] animals. The offspring generated by the first breeding (Slco1c1-CreER T2 ; LepR Fl/þ ) were crossed back with homozygous LepR
Fl to obtain Slco1c1-CreER T2 ; LepR Fl and LepR Fl animals. To induce recombination, tamoxifen was administered to mice (i.p., 1 mg, SigmaeAldrich, T5648, dissolved in 90% miglyol 812, 10% ethanol) every 12 h for 5 consecutive days at an age of 5e6 weeks. Cre-negative controls were also treated with tamoxifen. Slco1c1-CreER T2 ; LepR Fl mice that received tamoxifen are referred to as LepR beKO . Male littermate mice were used for all experiments. Mice with the inducible expression of HA-UPRT in brain endothelial cells were generated by crossing HA-UPRT Fl (JAX stock #021469) [28] with Slco1c1-CreER T2 animals. Mice with the expression of Zs-Green were generated by crossing LepR-Cre (JAX stock #008320) [29] with Zs-Green animals (JAX stock #007906) [30] .
Immunohistochemistry
The mice were anesthetized and transcardially perfused with ice-cold Ringer's solution followed by ice-cold paraformaldehyde (PFA, 4% in phosphate-buffered saline, PBS). Brains were post-fixed for 24 h in PFA (4%) and then cryoprotected by overnight immersion in a 30% sucrose solution. Brains were frozen in 2-methylbutane on dry ice.
Coronal cryosections (20 mm-thick) were incubated in PBS containing 0.3% triton and 3% bovine serum albumin (BSA) for 1 h to block unspecific binding. Then, sections were incubated with the following primary antibodies diluted in blocking solution overnight at 4 C: rat anti-CD31 (BD-Pharmingen, 553370, 1:400), mouse anti-leptin receptor (Abcam, ab43406, 1:200), chicken anti-vimentin (Thermo Fischer, PA1-16759, 1:400), rabbit anti-HA (Santa Cruz, sc-805, 1:300), goat anti-collagen IV (MERCK Millipore, AB769, 1:200), and rat anti-PV1 (BD-Pharmingen, 550563, 1:400). On the next day, sections were washed with PBS and subsequently incubated for 3 h at room temperature with the following fluorescently labeled secondary antibodies: donkey anti-rabbit Alexa Fluor 555 (Invitrogen, A and LepR beKO mice, we used a protocol that has been reported previously [31] . Freshly isolated vessel fragments containing pericytes and endothelial cells were either directly lysed for RNA purification, reverse transcription, and qPCR or they were plated for further purification of brain endothelial cells. After 2 weeks in culture, more than 95% of cells were endothelial cells and less than 5% were pericytes. The culture did not contain astrocytes, microglia, or neurons. RNA was isolated from primary brain endothelial cells using the NucleoSpin kit (Machereye Nagel), according to the manufacturer's protocol, and transcribed with avian myeloblastosis virus reverse transcription and random hexamer primers (Cloned AMV, First-stand synthesis kit, Invitrogen). The following primers were used for qPCR: leptin receptor (exon 9) forward 5 0 -GAC TTG CAG ATG GTC ACC CA-3 0 , leptin receptor (exon 10) reverse 5 0 -TGG GCT CAG ACG TAG GAT GA-3 0 , PCR product 122 bp; beta actin forward (exon 5) 5 0 -ATG GAA TCC TGT GGC ATC CAT- Fraction 2 &3 contained the radioactively labeled protein as determined by thin layer chromatography using ITLC-SG and 0.9% NaCl as the eluent. For in vivo experiments, the solution was used as was.
2.5.
125 I-leptin uptake Mice were anesthetized with urethane (4.0 g/kg i.p., SigmaeAldrich, U2857). The heart was exposed and the descending part of the aorta was clamped, leaving open only the branches to the upper part of the body. A cannula was inserted in the left ventricle and the brain was transcardially perfused with artificial plasma solution (123 mM NaCl, 4 mM KCl, 2.5 mM CaCl 2 , 1.8 mM MgCl 2 , 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 5.5 mM D-glucose, 6% dextran (MW 70,000), 20% washed sheep red blood cells) [33] containing 0.55 nM 125 I-leptin (21.6 mCi/ mg) for 30 min at a perfusion rate of 1 ml/min, as reported previously [34] . The vascular space was washed out with the same solution without the radiolabeled peptide for 10 min. CSF was sampled by puncturing the cisterna magna as reported previously [35] . Mice were decapitated, and the mediobasal hypothalamus, VTA, and cortex were dissected. After weighing samples 125 I activity was measured with a g-counter (Wallac Wizard2 2470 automatic g-counter, Perkin Elmer).
125 I-leptin uptake was expressed as (radioactivity in brain samples/g sample weight)/(radioactivity in artificial plasma solution/ml) as reported previously [36] .
Feeding studies
Mice were fed with either NCD (Ssniff EF, D12450B) or HFD (Ssniff EF, D12492 (I)) ad libitum. Energy intake was assessed by indirect calorimetry (see below) or by weighing food pellets in the cage. The metabolizeable energy of the HFD (21.6 Â 10 6 J/kg) consisted of fat (60%), proteins (19%), and carbohydrates (21%), while the NCD (15.1 Â 10 6 J/kg) contained fat (13%), proteins (20%), and carbohydrates (67%). Both diets were supplied as 10-mm pellets, which were half discarded and half refilled every 2 days.
Body composition The body composition of LepR
Fl and LepR beKO mice was measured by magnetic resonance spectroscopy (Bruker Minispec LF110) after 40 and 82 days on HFD or NCD.
Leptin treatment
Food intake and body weight were measured twice a day (17.30 pm, 30 min before "lights-off"; 8.00 am, 2 h after "lights-on"). After assessing baseline food intake and body weight for 3 days, recombinant mouse leptin (2 mg/kg, PeproTech 450-31) or vehicle were intraperitoneally injected twice a day at the same time points for 5 days. On the last day, mice were fasted overnight and sacrificed 45 min after the injection of leptin (3 mg/kg) or vehicle.
2.9. Indirect calorimetry Indirect calorimetry was performed with a ventilated, open-circuit system (PhenoMaster System, TSE). The mice were kept in ventilated chambers for 1 week under a 12-h lightedark cycle and at a constant temperature of 23 C. After allowing animals to adapt to the setup for 4 days, the following parameters were analyzed for 3 consecutive days. Locomotion was measured by a heat sensor. Food and water intake was measured every 10 s. The respiratory exchange ratio was estimated every 20 min as ratio of CO 2 produced (ml/h) to O 2 consumed (ml/h). Energy expenditure (MJ) was calculated as following: (0.0165 þ 0.00463 Â RER) Â O 2 consumed. The average daily energy expenditure over three days was plotted against the lean body mass of the same mouse.
Conditioned place preference test
Conditioned place preference (CPP) was tested in a three-chamber apparatus (TSE) consisting of a small middle chamber connected to two larger side chambers that differed in floor and wall texture ( Figure 5A ). The procedure took 14 days (overview in Supplementary  Figure 1A) . On day 1 and 2, mice received a free supply of sucrose pellets (65%, Ssniff) in their home cages. Subsequently, mice were food restricted to 60% of individual food intake at baseline from day 3 until the end of the experiment. On day 3, mice were placed in the middle chamber for 10 min to get familiar with the apparatus. The baseline preference for the two side chambers was assessed on day 4, wherein mice were allowed to freely move in the three chambers for 18 min. During the conditioning phase (day 5e13) mice were exposed to either sucrose pellets in the chamber that they preferred less during baseline testing or to normal chow in the preferred chamber. Sucrose pellets were provided on odd days and normal chow on even days for 18 min each. The preference value was evaluated on day 14, while mice had free access to all three chambers. Preference was calculated as:
Time in chamber with sucrose pellet Total timeÀtime in the middle chamber *100.
Conditioned two-bottle choice (BC)
During the BC test, the animals received a fixed amount of food and water every day. The test was performed in an operant chamber (Med Associates Inc.) which had two slots for water bottles on opposing sides of the cage ( Figure 5C ). Each bottle was equipped with a lickometer to detect the number of licks. The baseline preferred bottle position was tested for each mouse by providing a choice of two bottles, both containing water, for 10 min. During the following 8 days (overview in Supplementary Figure 1B ), mice were conditioned by providing free access to a bottle containing either water on the baseline preferred side or 0.8 M sucrose on the opposing side for 30 min per day. Sides and content were alternated each day. Mice were tested for 10 min by providing two bottles both containing water [37] . The preference value was calculated as:
ðLicks sucrose side=Total licksÞ*100:
3. RESULTS
LepR is involved in leptin transport into the brain
Using LepR-cre;Zs-Green mice in which Zs-Green reflects expression of LepR, we confirmed previous reports that LepR is expressed in crucial access points to the brain [38] , including brain capillaries ( Figure 1A) , cells in the mediobasal hypothalamus (Supplementary Figure 2A and B), and epithelial cells of the choroid plexus (Supplementary Figure 2C) . To test the function of LepR at these sites, we aimed to delete LepR in a cell type-specific manner. We used the Slco1c1-CreER T2 Cre driver line, which allows for cell type-specific recombination in brain endothelial cells and in epithelial cells of the choroid plexus but does not cause recombination in endothelial cells of other tissues [26] . Because recombination in the mediobasal hypothalamus of Slco1c1-CreER T2 mice has not been studied so far, we crossed Slco1c1-CreER T2 with HA-UPRT Fl mice as a reporter line. Staining of HA-UPRT confirmed recombination in brain endothelial cells ( Figure 1B) . As reported previously recombination seemed to affect mainly capillaries [39] . There was no co-staining with PV1, a marker of fenestrated vessels in the median eminence (Supplementary Figure 3A) demonstrating that recombination is specific for non-fenestrated vessels of the BBB. Although expression of Slco1c1 has been reported in tanycytes [40] , we found no HA-UPRT in these cells ( Figure 1C ). In accordance with the recombination in the choroid plexus reported previously [26] , HA-UPRT was detected in epithelial cells of the choroid plexus. In summary, the Slco1c1-CreER T2 line targets the choroid plexus and endothelial cells of the BBB, two sites where leptin enters the brain, but it spares the fenestrated capillaries and tanycytes of the mediobasal hypothalamus. We crossed Slco1c1-CreER T2 mice with a LepR Fl line, in which exon 1 is flanked by loxP sites [3] . All LepR isoforms include exon 1 and are targeted by this strategy. We assessed LepR expression three weeks after starting the tamoxifen treatment. Immunostainings showed clear reduction in brain endothelial cells ( Figure 1D ) and epithelial cells of the choroid plexus (Supplementary Figure 3B) . In accordance with results obtained in the HA-UPRT Fl reporter mouse line, there was no change in the LepR staining in tanycytes (Supplementary Figure 3C) Figure 1E ). To investigate whether LepR is involved in leptin transport, we performed in situ brain perfusion with a physiological concentration of 125 I-labeled leptin (0.55 nM). This technique allows for the assessment of leptin uptake in vivo without interference of confounding factors present in blood [14] . The results showed a significant reduction in several brain areas of LepR beKO mice ( Figure 1F ). In the VTA and cortex, 125 I-leptin uptake was more severely impaired (about 60%) than in the mediobasal hypothalamus (about 40%). Thus, LepR in brain endothelial and epithelial cells contributes to leptin transport into the CNS.
LepR in brain barriers is involved in regulation of body weight and energy intake
After having demonstrated that LepR is involved in leptin transport into the brain, we aimed at characterizing the physiological function of the LepR-mediated leptin transport. For this purpose, we monitored body weight of LepR Fl and LepR beKO mice for 91 days. Body weight gain and energy intake did not significantly differ between the two genotypes (Figure 2A and B) . However, elevating leptin levels by administering exogenous leptin (2 mg/kg, i.p., 2 times per day for 5 days) only reduced energy intake in LepR Fl controls but not in LepR beKO mice ( Figure 2C ). Despite this difference in leptin sensitivity, the number of pSTAT3-positive cells in the ARC was not altered between the genotypes 45 min after the last leptin injection ( Figure 2D ), suggesting that the difference in energy intake was not driven by leptin-sensitive cells in the ARC. To elevate endogenous leptin levels, we fed mice with HFD or with NCD for comparison. While the two genotypes again did not differ in body weight on NCD, on HFD LepR beKO animals gained more body weight than LepR Fl mice ( Figure 3A ). Magnetic resonance spectroscopy revealed no difference in body composition of mice fed with NCD ( Figure 3B ), whereas on HFD LepR beKO mice showed significantly larger fat depots than LepR Fl controls at 82 days ( Figure 3C ). The energy intake was higher in LepR beKO mice than in LepR Fl controls at Figure 3D ), when body weight was still not markedly increased, suggesting altered food ingestion as a cause for the successive increase in body weight. Notably, the diurnal pattern of energy intake was similar between LepR Fl controls and LepR beKO mice on NCD ( Figure 3E ), but on HFD LepR beKO mice exhibited a disturbed rhythm with an increased energy intake mainly during the light (resting) phase ( Figure 3F ). For further characterization of LepR functions in brain barriers, we assessed additional metabolic parameters using indirect calorimetry. As expected from the data on energy intake and body weight, LepR Fl and LepR beKO mice did not differ in water intake, respiratory exchange ratio, locomotion, and energy expenditure when fed NCD (Figure 4Ae  D) . Also on HFD, the two genotypes were similar in these parameters (Figure 4AeD ). In addition, blood glucose levels were similar between the genotypes on both diets ( Figure 4E ). After 82 days of HFD, leptin plasma levels were increased in LepR beKO mice compared to LepR FL controls reflecting the larger fat depots in mice deficient of LepR in brain barriers ( Figures 4F and 3C ). Elevated plasma leptin levels are associated with reduced release of soluble LepR from tissues [41] . In line with this concept, we found that plasma concentrations of soluble LepR were decreased in HFD-induced obese mice ( Figure 4G ), although LepR mRNA expression in cerebral vessel fragments was not altered by the diet (NCD, 1.0 AE 0.2 2 ÀDDCT , n ¼ 6; HFD, 0.9 AE 0.4 2 ÀDDCT , n ¼ 5) as reported previously [22] . Interestingly, plasma concentrations of soluble LepR did not differ between genotypes ( Figure 3G ) in contrast to the elevated soluble LepR levels in a previously reported mouse model of pan-endothelial LepRb deficiency [42] . In summary, LepR in brain endothelial and epithelial cells was required to control food intake under HFD conditions.
3.3. Leptin receptor on brain endothelial cells modulates the response to reward HFD is associated with food reward [43] . Therefore, we directly investigated whether LepR in brain barriers modulates food reward. In the conditioned place preference (CPP) paradigm ( Figure 5A ), mice of both genotypes developed a preference for the chamber that was paired with sucrose pellets. However, conditioning was more pronounced in LepR beKO than in LepR Fl mice ( Figure 5B ), suggesting that LepR beKO mice were more susceptible to the rewarding effects of palatable food. This conclusion was supported by the conditioned twobottle choice (BC) test in a separate cohort of animals ( Figure 5C ). After 8 days of conditioning, mice of both genotypes drank more from the bottle that used to contain sucrose solution, although it was only filled with water during testing. Similar to the observation in the CPP, LepR beKO mice showed a higher preference for the bottle conditioned to sucrose than LepR Fl animals ( Figure 5D ) confirming the notion that LepR-mediated leptin transport inhibits food reward.
DISCUSSION
Targeting LepR in brain barriers
The routes by which leptin reaches the brain have been debated almost since its discovery more than two decades ago [1] . While leptin may freely access brain regions adjacent to circumventricular organs, the long isoform of LepR that is involved in signaling is also expressed outside of circumventricular organs [44] . This suggests that leptin is transported through barrier forming cells to act on these regions. Three cell types provide potential gates for leptin entry into the brain: (1) endothelial cells forming the BBB [14] ; (2) epithelial cells forming the blood-CSF barrier in the choroid plexus [15] ; and (3) tanycytes in the mediobasal hypothalamus that form a barrier between median eminence and the CSF by expressing tight junctions [17, 45, 46] . So far, the functional significance of these three access points for body weight regulation has remained largely unclear. Ambiguity also exists with regard to the molecular identity of the leptin transporter. The prime candidate is LepR, as it is expressed in brain endothelial and epithelial cells as well as in tanycytes [17e21]. However, conflicting data about its role in leptin transport have been obtained from LepR deficient animals [22, 23] , probably because these reports solely relied on leptin uptake, a parameter that may be influenced by the increased permeability of the BBB in obesity [47] . Besides LepR, LRP1 and LRP2 qualify as alternative transporters, at least in vitro [48, 49] . Deletion of LRP2 in central and peripheral endothelial cells and in hematopoietic cells triggers obesity, but the phenotype is more complex and includes neurodegenerative and inflammatory changes in the brain making conclusions for body weight regulation difficult [50, 51] . To investigate the role of LepR for leptin transport to the brain without interfering signals from the periphery, we deleted LepR in brain endothelial and epithelial cells (LepR beKO mice). Two features distinguish the new LepR beKO mouse model from a similar mouse line that has been reported before [42] . First, all isoforms of LepR are deleted in LepR beKO mice, whereas previous studies only targeted the long LepR isoform resulting in the compensatory up-regulation of soluble isoforms. Second, by limiting LepR deletion to brain barriers, we aimed to avoid peripheral effects. Fenestrated capillaries in the median eminence as well as tanycytes do not show recombination in LepR beKO mice. Thus, the approach targets two of the access points of leptin, the BBB and the blood-CSF barrier. In LepR beKO mice, LepR mRNA expression in primary brain endothelial cells was reduced by about 60%, in contrast to higher recombination rates that we had observed in previous studies with the Slco1c1-CreER T2 driver line [26, 52] . As noted previously, the floxed locus in LepR Fl mice does not seem to be as easily accessible for the Cre recombinase as in other mouse lines [3] . Remaining LepR in the BBB or the blood-CSF barrier may explain why leptin uptake in the cortex or VTA was reduced by about 60%. The reduction of leptin uptake in the mediobasal hypothalamus and CSF of LepR beKO mice was less (40%) and not statistically significant, probably due to tanycytes and fenestrated capillaries that were not targeted by our approach. In contrast, LepR is efficiently deleted in epithelial cells of the choroid plexus of LepR beKO mice implying that tanycytes and not epithelial cells of the choroid plexus control leptin uptake into the CSF unless there are other leptin transporters in the choroid plexus. Overall, our study clearly demonstrates that LepR contributes to leptin transport into the brain.
Functional consequences of reduced leptin transport
The impaired leptin transport in LepR beKO mice did not affect food intake or body weight on NCD (Figure 2A and B) . Only when high doses of leptin were peripherally administered, LepR beKO mice were less anorexic than controls ( Figure 2C ). We predict that the sensitivity to intracerebrally administered leptin would be preserved in LepR beKO mice on NCD. Interestingly, the blunted effect of peripheral leptin on food intake was not associated with a lower number of pSTAT3-positive cells in the ARC, the nucleus that is of primary importance for homeostatic feeding, suggesting that leptin transport across brain barriers modulates feeding behavior through other neuronal circuits. On a rewarding HFD LepR beKO mice were more susceptible to obesity. Their energy intake was increased, especially during the resting (light) phase ( Figure 3F ). Notably, a disturbed circadian rhythm of food intake behavior in obese mice may further aggravate obesity [53e55]. Water intake, locomotion, and energy expenditure clearly did not differ between the genotypes (Figure 4AeD) suggesting that obesity was likely caused by hyperphagia of the rewarding HFD, when leptin uptake in the brain was impaired. Glucose tolerance and insulin plasma concentrations in LepR beKO mice will have to be investigated by future studies. More direct evidence for the role of LepR-mediated leptin transport in the regulation of food reward comes from independent experiments studying food preference in lean mice fed with NCD. In both CPP and BC paradigms, mice deficient of LepR in brain barriers developed a stronger preference for the reward stimulus. The enhanced sensitivity to food reward leads to a higher energy intake when mice were fed with the rewarding HFD. Our data indicate that LepR in brain endothelial and epithelial cell is required for leptin to reach its target cells in the reward system of the brain. It is well known that leptin is able to regulate the mesoaccumbens dopamine pathway [56] and that in leptin deficient animals the reward value of palatable food is higher than in wild-type mice [57] . In the absence of LepR in the VTA [6] or in the lateral hypothalamic area [7] dopaminergic neurons in the mesolimbic system show an increased sensitivity to high caloric molecules present in plasma. The present study demonstrates that leptin transport by LepR is required for leptin to exert its inhibitory effects on reward circuits in the brain. The transport of leptin across the BBB has a Km of about 1 nM [36] , a value that is in good accordance with the affinity of both short and long isoforms of LepR [58] . In contrast, leptin binds to LPR2 with a much lower affinity and with a dissociation constant of 200 nM [59] suggesting LepR as the primary binding site. In accordance with this, endothelial and epithelial cells in the brain highly express short isoforms of LepR, including LepRa [18e21]. Interestingly, deleting LepRa leads to a very similar phenotype to that which we have observed in LepR beKO mice [60] . Mice deficient of LepRa [60] have a normal body weight on NCD but aggravated obesity on HFD. The latter study and our data converge on the concept that leptin transport across brain barriers that is mediated by LepR modulates food reward but seems to be dispensable for the homeostatic control of feeding.
CONCLUSIONS
We found that LepR in the BBB and the blood-CSF barrier is at least partially required for leptin uptake by the brain and for the regulation of food intake, particularly of food reward. Previous work demonstrated that LepR is required for leptin transport by tanycytes in the mediobasal hypothalamus [17] . Overall, LepR is essential both for leptin transport into the brain and for its multiple effects in the CNS and the periphery. This dual role of LepR in signaling and transport is attributed to distinct long and short isoforms, respectively, but they share the extracellular leptin-binding domains, a fact that may pose an obstacle for the development of peripheral leptin inhibitors. Such inhibitors have been suggested as a therapeutic principle for some forms of cancer and other diseases [61] . In view of our data, it may be difficult to develop competitive leptin antagonists that do not reach the brain and are free of central metabolic side effects. In obesity, leptin transport into the brain is impaired [47] . Our data demonstrate that a deficit in leptin transport to the brain is able to enhance food reward, providing a potential explanation for the increased sensitivity to food reward in overweight subjects [62] . In obesity, pathological leptin transport is not due to a simple downregulation of LepR transcription in brain vessels [22] . However, maintenance of LepR levels at the cell surface, binding of leptin, and the subsequent receptor-mediated transcytosis involve multiple cellular processes, including trafficking, shedding, and glycosylation [63, 64] , that may provide targets to optimize leptin transport and to treat obesity.
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